当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Marcas Pape
Background: Different levels of breast cancer mortality reduction have been shown in recent case-control studies on the efficacy of population-based breast cancer screening. We looked into how the case-control research design's elements, such as the definition of cases and exposure to screening, affected these discrepancies.
Materials and procedures: We looked at six case-control studies that were carried out in South Australia, The Netherlands, Wales, Iceland, central and northern Italy, and East Anglia (UK).
Results: The difference between screened and unscreened women's breast cancer mortality decreased from 38% to 70% in several case-control studies. We observed design changes, such as whether to include or exclude the first years of screening and the self-selection bias correction factor.
Conclusions: The case-control studies' designs were generally comparable. It is highly improbable that changes in the case-control study design are to blame for the variances in the amount of breast cancer mortality reductions. These variations must be the result of additional elements, such as how the service screening programme is set up and the attendance rate. These case-control studies' estimated decrease in breast cancer mortality suggests that the impact of contemporary mammographic screening is at least consistent with the benefit noted by the previous
randomised screening trials.